Alessandro Galluzzo

RT @ESC_Journals: Supplemental oxygen in #AHF - check the #SciencePulse interview focusing on the results of REDOX-AHF trial #EHJACVC @drmilicaa @EHJACVCEiC @TharusanT @alegallu @JohannesGrand @MajaCikes

RT @escardio: Present at the world-leading acute cardiovascular congress and help shape the split-second decisions that save lives. Submit your science for #ACVC27 and take your place among experts redefining care Deadlines - Abstracts: 29 Oct | Clinical cases: 5 Nov #ACVC_ESC @ACVCPresident

Missed the #ESCCongress session on nsMRAs in HF? Catch it on demand for an excellent overview of landmark evidence and practical implementation. Rewatch Michael Böhm’s precise recap, @MajaCikes’ brilliant presentation and Muthiah Vaduganathan’s pragmatic perspective.@escardio

RT @SeguraCardio: 🚨 Fifth Universal Definition of Myocardial Infarction (2026) #ESC26 #ESCCongress #Guidelines #MyocardialInfarction

RT @franciscojlk: Good morning from Munich! ☀️ It is the final day of #ESCCongress 2026, but there is still plenty of science ahead. My five sessions not to miss today: 🫀 08:15 | HOT LINE 10 New evidence on syncope, CRT and rhythm monitoring. ⚡ 10:15 | Cardiogenic shock: different aspects in diagnosis Including ScvO₂, PCO₂ gap, microcirculation and lactate trajectories. 🤖 11:15 | Artificial intelligence modelling and cardiovascular disease Another look at how machine learning is moving into cardiovascular phenotyping and prediction. 🔥 13:00 | HOT LINE 11 EVAOLD, ISOLEDS, CorCal and CoCAP: coronary intervention, imaging and prevention. 🚑 14:15 | HOT LINE 12 Out-of-hospital cardiac arrest, including DISCO and the HeartRunner Trial. One last day to learn, debate and connect. See you around the Congress! ❤️ @escardio @ESC_Journals #ESCCongress #ESC2026 #Cardiology #HeartFailure #CardiogenicShock #AI #CardiacArrest

H-HeFT: neutral or underpowered? H-ISDN missed primary outcome (HR .90), but mortality HR was .72 and pooled RCTs suggest benefit (.71). Discontinuation for hypotension and constraints of investigator-led trials cloud interpretation. The H-ISDN debate is not over. #ESCCongress

LIBREXIA-ACS: the factor XIa hypothesis falls short after ACS. Milvexian 25 mg BID added to antiplatelet therapy did not reduce CV death, MI or ischaemic stroke (HR 1.05; 95% CI 0.91–1.21), but did not increase BARC 3c/5 bleeding. The unmet need remains. #ESCCongress

@drmilicaa @KralerSimon @franciscojlk @OtiliaTica1 @HelleSoholm @rafavidalperez

Are we using ECPELLA in AMI-CS just out of hope? A meta-analysis based on observational data suggests survival benefit—despite more complications—but randomised proof is still needed. Insightful perspectives from GeorgeChatzis&@thiele_holger. Awaiting UNLOAD-ECMO. #ESCCongress

Brilliant session about novelties in CS at #ESCCongress: patient profiling, phenotypic and risk stratification translate into active change in treatment strategies @escardio: And teamwork can lead to better outcomes

@JaninePoss JacobMoller AlainCombes @BenediktSchrage @HannahSchaubro1 @ATycinska Zuzana Motovska

Is the IABP chapter closed or does CS need a strategy rather than a one-size-fits-all device? Alice Sacco: “IABP is not dead. Routine IABP is.” Ask: which patient, which physiology, which target—and what exit strategy? @escardio #ESCCongress #cvacute

Cardiogenic shock is not just a pump problem—and lactate is not the whole story. Can we intercept the Titanic before it sinks? Sabri Soussi calls for “CS 2.0”: earlier diagnosis before overt hypoperfusion @soussi_sabri @escardio #ESCCongress #cvacute

Starting at full speed with Day 1 at #ESCCongress: don’t miss the new ESC HF Guidelines, novelties about cardiogenic shock and the first Hot Line trials. 🔥🔥🔥 Follow the science with @escardio:

@drmilicaa @KralerSimon @franciscojlk @OtiliaTica1 @HelleSoholm @rafavidalperez

Tomorrow, Munich becomes the heart of cardiology. 🫀 #ESCCongress 2026 begins! Follow @escardio and join the conversation:

RT @escardio: The countdown is ON! #ESCCongress lands in Munich this Friday! Get ready to meet our incredible Social Media Ambassadors 🙌 your front-row seat to everything happening on the ground. 📲 Follow their journey 💬 Join the conversation 🔥 Catch the hottest updates & behind-the-scenes highlights See you in Munich ❤️ @LaFusini @YBououdina @slumberbell @hrt01a @veramasloo @JacopoImberti @Sharon_Man @pan_pantelidis @PanteleimonPap2 @corneliacrm @corneliacrm @corneliacrm @franciscojlk @OtiliaTica1 @alegallu @rafavidalperez @Amir_Askn_ @DavideMei93 @DavideMei93 @a_sorropago @IlkeCelikkale @Giulia_Botti_ @Giulia_Botti_ @PopiolekKalisz @Ajar_kocak @KoKoMaung_ @Sampathkpt @GalTsaban @GalTsaban @J_Hendriks1 @MarielaAcunaM1 @martha_kyriakou @GawalkoMonika @rbcasado @maria_bergami @MariaCGatto @danmjohnson @liberale_luca @LDiVenanzio @fabri_bon87

RT @ACVCPresident: The final countdown of #AcuteCVDays is on ⏳ Week 5 challenges the often-asked question - can the contemporary management of #heartfailure prevent severe forms of #AHF and development of hashtag#CardShock? 🏥 And how should we proceed if this occurs? This week's resources are done in collaboration with @HFA_President #HFA_ESC Visit our website and enjoy You can start with an MCQ ⬇️

RT @escardio: #ACVC26 abstract submission deadline extended, giving you more time to share your work & shape practice in acute care. Bring your science to a community built on teamwork, learning, and action. Deadlines: Abstracts: 4 November | Clinical cases: 6 November #ACVC_ESC @ACVCPresident

🌍 IV vasodilators in acute HF: widely taught, rarely used? Survey of 170 cardiologists from 32 countries shows heterogeneity in indications, agents & monitoring. Clear need for trials! 👉 Read the full paper:

@mauriziobertaina @WilfriedMullens @JulieVishram @Massimi78530343 @HannahSchaubro1 @ferdinandovarbella @LucaMonzo @FinnGustafsson @frankruschitzka